In clinical trials1,2,10Evidence: Large human trialsMetabolic and weight

Retatrutide1

Also called LY34379431

Key takeaway

Retatrutide is an experimental peptide from Eli Lilly that activates the receptors for three hormones: GIP, GLP-1 and glucagon.1,4,5 It is not an approved drug. FDA states that it is not a component of any FDA-approved drug, has not been found safe and effective for any condition, and cannot be used in compounding under federal law.2 Published randomized trials report weight loss and lower blood sugar, including a 338-person Phase 2 obesity trial and a 537-person Phase 3 diabetes trial. Several other Phase 3 trials are registered on ClinicalTrials.gov.3,5,6,9 FDA says it has warned companies for marketing retatrutide to consumers, including products falsely labeled as being for research purposes.2

Retatrutide at a glance

What it isAn investigational agonist of the GIP, GLP-1 and glucagon receptors, developed by Eli Lilly and also known as LY3437943.1,5
FDA statusNot FDA-approved. FDA states that retatrutide is not a component of an FDA-approved drug and cannot be used in compounding under federal law.2
Human evidenceRandomized trials reported in journals: two Phase 2 trials and one Phase 3 diabetes trial. Other Phase 3 trials are registered.3,4,5,6
Evidence strengthLarge randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned

What is retatrutide?

Retatrutide is an experimental peptide being developed by Eli Lilly and Company, which ClinicalTrials.gov lists as the sponsor of the trial record cited on this profile. It is also known by its development code, LY3437943.1

The published trial reports describe it as a single molecule that activates the receptors for three hormones: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon.4,5

How is retatrutide thought to work?

The 2023 New England Journal of Medicine report describes retatrutide as a triple-hormone-receptor agonist, meaning one molecule that acts on three hormone receptors.3

The sources reviewed here do not establish how much each of the three receptors contributes to the effects reported in trials.3,4,5

What do human studies show?

In the Phase 2 obesity trial, 338 adults with obesity, or overweight with a weight-related condition, were randomized to retatrutide or placebo. At 48 weeks, average body-weight change ranged from −8.7% to −24.2% across the retatrutide groups, compared with −2.1% with placebo.3

In that trial, gastrointestinal events were the most common adverse events, and increases in heart rate peaked at 24 weeks before declining.3

A Phase 2 trial of 281 adults with type 2 diabetes reported changes in HbA1c, a measure of long-term blood sugar, ranging from −0.43 to −2.02 percentage points across the retatrutide groups at 24 weeks, compared with −0.01 for placebo and −1.41 for the active comparator.4

In TRANSCEND-T2D-1, a Phase 3 trial of 537 adults whose type 2 diabetes was not controlled by diet and exercise, HbA1c fell by 1.69 to 1.94 percentage points across the retatrutide groups at 40 weeks, compared with 0.81 with placebo. Gastrointestinal events were common, and 2% to 5% of participants in the retatrutide groups stopped because of adverse events, compared with none on placebo.5

That report recorded two deaths in one retatrutide group, which the authors considered unrelated to study treatment.5

These trials followed participants for 24 to 48 weeks for their main results, which does not show long-term outcomes, rare harms, or what happens after treatment stops.3,4,5

What the evidence base contains

  • Large randomized human trial A 48-week double-blind, randomized, placebo-controlled Phase 2 trial in 338 adults with obesity, or overweight with a weight-related condition, published in The New England Journal of Medicine.3
  • Controlled human trial A randomized, double-blind Phase 2 trial with placebo and active comparator groups in 281 adults with type 2 diabetes at 42 U.S. centers, published in The Lancet.4
  • Large randomized human trial TRANSCEND-T2D-1, a 40-week double-blind, randomized, placebo-controlled Phase 3 trial in 537 adults with type 2 diabetes, published in The Lancet.5
  • Registered trial without results Phase 3 trials in obesity with cardiovascular disease (NCT05882045) and in obesity with type 2 diabetes or sleep apnea (NCT05929079), listed as completed in registry records updated July 30, 2026. Their results are not part of the sources cited here.6,7
  • Registered trial without results A Phase 3 trial in people with cardiovascular or chronic kidney disease (NCT06383390), listed as active, not recruiting in its August 24, 2026 registry record.9

Evidence-strength label: Large randomized human trials. How this label is assigned

Is retatrutide FDA-approved?

No. FDA’s page on unapproved GLP-1 drugs, current as of October 1, 2026, states that retatrutide is not a component of any FDA-approved drug and has not been found safe and effective for any condition.2

The same page states that retatrutide and cagrilintide cannot be used in compounding under federal law.2

FDA says it has warned telehealth companies for marketing unapproved drugs such as retatrutide, including directly to consumers, distributors of active ingredients for selling retatrutide to compounders, and outsourcing facilities for repackaging it.2

FDA also says it has warned companies that sold unapproved drugs containing retatrutide falsely labeled as being for research purposes or not for human consumption, and it urges consumers to avoid these products, which it says are of unknown quality.2

Retatrutide remains in clinical trials. None of the sources reviewed here reports an approval of retatrutide in any country.2,10

Timeline

  1. Results of two Phase 2 trials, in obesity and in type 2 diabetes, are published.3,4
  2. Results of TRANSCEND-T2D-1, a Phase 3 trial in type 2 diabetes, are published in The Lancet.5
  3. FDA’s page on unapproved GLP-1 drugs, which says retatrutide cannot be used in compounding, is updated, as shown by its content-current date.2

What is still unknown?

Whether the weight and blood-sugar results lead to fewer heart attacks, strokes or other long-term complications: the published trials measured weight and HbA1c over 24 to 48 weeks.3,5

What the completed Phase 3 trials found: their results are not part of the sources cited on this page.6,7,8

What is in retatrutide products marketed outside clinical trials, which FDA describes as unapproved and of unknown quality.2

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Retatrutide: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Retatrutide are the records PeptideScanner has selected and published, not every registration or paper about Retatrutide. A daily check adds newly updated registrations and newly indexed papers that pass the publication checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence questions

Start with the question you have

Open the cited status, reviewed human evidence, unresolved limits, or profile changes.

Evidence summary

What the cited records show

What is its status in the cited records?

In clinical trials; not FDA-approved. Published randomized trials, including a Phase 3 diabetes trial, report weight and blood-sugar changes over up to 48 weeks. FDA states that retatrutide has not been found safe and effective for any condition and has warned companies marketing it to consumers.↗↗↗↗↗

Status sources checked through July 22, 2026. See status sources and coverage →

What do the reviewed human studies say?

Human evidence reviewed September 15, 2026 · Review version 2.

Review source snapshots checked September 15, 2026 · Integrity checked September 15, 2026.

Three selected reports cover early retatrutide studies and the later TRANSCEND-T2D-1 phase 3 diabetes trial. Populations, comparators and primary endpoints differ across the studies.↗↗↗

What the reviewed sources report

Selected trials reported weight reduction and improved glycated hemoglobin. The newer phase 3 diabetes study supports a glycemic effect in its studied population, but these reports do not establish prevention of long-term complications; gastrointestinal adverse events and discontinuations matter.↗↗↗

What remains unresolved?

  • Do Phase 3 trials confirm durability, rare harms, and clinically important outcomes across more diverse populations?↗↗
  • How do participant flow, missing outcomes, protocol history and linked corrections affect interpretation of the selected reports?↗↗↗

Read study designs, results, limitations, and sources →

Reviews summarize selected studies; their scope and limitations are shown above.

Read the full Human Evidence Review

Supervised synthesis

What do selected human studies report about Retatrutide?

Manually reviewed September 15, 2026 · version 2

Browse all Human Evidence Reviews · Open preserved synthesis version 2 →

Three selected reports cover early retatrutide studies and the later TRANSCEND-T2D-1 phase 3 diabetes trial. Populations, comparators and primary endpoints differ across the studies.123

Bottom line from this bounded source set

Selected trials reported weight reduction and improved glycated hemoglobin. The newer phase 3 diabetes study supports a glycemic effect in its studied population, but these reports do not establish prevention of long-term complications; gastrointestinal adverse events and discontinuations matter.123

Reviewed study record

Phase 2 obesity trial

Design

A double-blind, randomized, placebo-controlled Phase 2 trial followed participants for 48 weeks and assessed body-weight change and safety.1

Population

The trial enrolled 338 adults with obesity, or overweight plus at least one weight-related condition.1

Outcomes reported

At 48 weeks, reported mean body-weight change ranged from -8.7% to -24.2% across retatrutide groups, compared with -2.1% for placebo. Gastrointestinal events were the most common adverse events, and heart-rate increases peaked at 24 weeks before declining.1

Limitations

This was a sponsor-funded Phase 2 trial with 48-week follow-up; it was not a long-term cardiovascular-outcomes or rare-harms study.1

Reviewed study record

Phase 2 type 2 diabetes trial

Design

A randomized, double-blind, placebo- and active-comparator-controlled Phase 2 trial evaluated glycated hemoglobin at 24 weeks and body weight at 36 weeks.2

Population

The trial randomized 281 adults with type 2 diabetes and elevated body-mass index at 42 U.S. centers; 275 were included in efficacy analyses.2

Outcomes reported

At 24 weeks, reported glycated-hemoglobin changes ranged from -0.43 to -2.02 percentage points across retatrutide groups, compared with -0.01 for placebo and -1.41 for the active comparator. Reported body-weight change at 36 weeks ranged from -3.19% to -16.94% across retatrutide groups.2

Limitations

The sponsor-funded trial had 36-week follow-up, 79% completed treatment, and 84% of participants were White; those features limit conclusions about durability and generalizability.2

Reviewed study record

TRANSCEND-T2D-1: phase 3 diabetes study

Design

A blinded randomized placebo-controlled trial assessed 40-week glycated hemoglobin change under NCT06354660.3

Population

The trial randomized 537 adults with type 2 diabetes inadequately controlled with diet and exercise alone.3

Outcomes reported

Under the treatment-regimen analysis, HbA1c decreased by 1.69–1.94 percentage points across active groups versus 0.81 with placebo. Gastrointestinal events were common; adverse-event discontinuations occurred in 2–5% of active groups and none of the placebo group.3

Limitations

HbA1c and weight changes do not establish prevention of long-term complications. The report recorded two deaths in one active group, which the authors considered unrelated to study treatment; it reported no severe hypoglycemia.3

Reviewed source set

  1. PubMed · 37366315Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial ↗PubMed PMID 37366315 · EFetch XML reviewed 2026-08-18 · payload SHA-256 167232d6f5d1818faabbc3d98c283b2ffad85563d5e10720f8e23347bba1ad1b
    No registered Crossref update in the reviewed snapshotChecked August 19, 2026 for DOI 10.1056/nejmoa2301972. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
  2. PubMed · 37385280Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA ↗PubMed PMID 37385280 · EFetch XML reviewed 2026-08-18 · payload SHA-256 766a11f2d979da96a8a2b79353159b0e0472215d1e391b8f8f5d09a142c5fdcd
    No registered Crossref update in the reviewed snapshotChecked August 19, 2026 for DOI 10.1016/s0140-6736(23)01053-x. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
  3. PubMed · 42250575Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. ↗PubMed PMID 42250575 · EFetch XML reviewed 2026-09-15 · payload SHA-256 c7b0d7e8d9f2053a0083809311fa312b449f6271b7cde41ea747e8bdf0a318c4
    No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1016/s0140-6736(26)00967-0. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
Official-source readings

Official-source update

Reviewed 2026-09-19 · Preserved version 2

Investigational status remains separate from trial progress

FDA’s September 1, 2026 page states that retatrutide is not a component of an FDA-approved drug and cannot be used in compounding under federal law. FDA source ↗

More findings and the sources behind them

Selected sponsor-submitted ClinicalTrials.gov records retrieved September 19, 2026, with design, population, endpoint and result-availability checks. This does not complete a registry search or replace primary-publication appraisal. Earlier dated FDA and registry findings remain separately attributed below.

TRIUMPH-1 is marked completed

The August 21 registry record for NCT05929066 reports 2,335 actual participants and April 30, 2026 completion. Its registered outcomes include weight change, sleep-apnea and knee-osteoarthritis subsets. The retrieved record has no posted summary results; completion alone is not an efficacy finding. NCT05929066 ↗

Cardiovascular and kidney outcomes are still being studied

NCT06383390 is active, not recruiting, in its August 24 record. It lists cardiovascular and kidney composite endpoints, estimated enrollment of 10,000, and estimated completion in February 2029. No summary results are posted in the retrieved record. NCT06383390 ↗

The obesity trial’s primary endpoint was at week 24

NCT04881760 enrolled 338 participants without diabetes. The registered primary endpoint is weight change at week 24, even though the treatment period lasted 48 weeks. The later weight result is a different time point. NCT04881760 ↗

The registry analysis excludes some post-discontinuation data

The primary obesity analysis uses participants with baseline and post-baseline measurements and excludes data after study-drug discontinuation. It therefore does not describe the outcome of assigning treatment regardless of whether everyone continued it. NCT04881760 ↗

The diabetes trial has a different endpoint and comparator

NCT04867785 enrolled 281 participants with type 2 diabetes, with placebo and dulaglutide comparator groups. Its primary endpoint was 24-week HbA1c change; weight results should not replace that registered question. NCT04867785 ↗

Rescue treatment changes the diabetes analysis population

The posted HbA1c analysis excludes data after permanent treatment discontinuation or initiation of rescue medication. This qualification belongs alongside effect estimates when comparing the registry with a paper or a different trial. NCT04867785 ↗

What remains to be checked

  • Reconcile phase 2 registry estimates with primary publications and preserve time points and estimands.
  • Appraise newer phase 3 reports and follow cardiovascular/kidney outcomes; missing registry results do not imply no publication.
Source dates and review coverage

PDF citations use file page numbers. Named webpage sections and registry fields identify the portions read. These are selected readings, not complete source coverage.

  • FDA concerns with unapproved GLP-1 drugs ↗

    Source dated 2026-09-01; retrieved 2026-09-16.

    • Concerns with compounded versions of these drugs
    • Salt forms should not be used to compound semaglutide
    • Adverse events related to compounded versions of semaglutide and tirzepatide
    • Retatrutide and cagrilintide cannot be used in compounding

    SHA-256: bfb6cd2a11e3f8e20bedfeed0e0d554205c76dd83f473956deb82afc186e51cc

  • TRIUMPH-1 · NCT05929066 ↗

    Source dated 2026-08-21; retrieved 2026-09-16.

    • protocolSection.identificationModule
    • protocolSection.statusModule; hasResults
    • protocolSection.designModule; protocolSection.outcomesModule.primaryOutcomes

    SHA-256: 2a606fc27966954db54215572c5b8dce1fbe1d25910a88c0b4efebe1fda60795

  • TRIUMPH-OUTCOMES · NCT06383390 ↗

    Source dated 2026-08-24; retrieved 2026-09-16.

    • protocolSection.identificationModule
    • protocolSection.statusModule; hasResults
    • protocolSection.designModule; protocolSection.outcomesModule.primaryOutcomes

    SHA-256: 92fbfee77c8e9b0797c4cf847951faee64e617d3b1e940f2123711936eba886b

  • A Study of LY3437943 in Participants With Type 2 Diabetes ↗

    Source dated 2023-07-03; retrieved 2026-09-19.

    • protocolSection.identificationModule, designModule and armsInterventionsModule
    • resultsSection.outcomeMeasuresModule

    SHA-256: d982d0da7ad7e0331422e07f197da1d47a7ed1febaa74be7d807bc6a8512ee2b

  • A Study of LY3437943 in Participants Who Have Obesity or Are Overweight ↗

    Source dated 2023-09-13; retrieved 2026-09-19.

    • protocolSection.identificationModule, designModule and armsInterventionsModule
    • protocolSection.eligibilityModule and armsInterventionsModule
    • resultsSection.participantFlowModule
    • protocolSection.outcomesModule
    • resultsSection.outcomeMeasuresModule

    SHA-256: 02ff67711c363c67a5a141a183cc3f734d4702e1b3877385214a39abc81b20b4

Open versioned findings and source records →

Research coverage and study families

Search and screening record checked 2026-09-15. Counts describe records, not independent trials. Full-text appraisal is separate from an abstract review.

Open machine-readable coverage and record decisions →

PubMed search

Catalog-name and calibrated alias discovery for human evidence review. Complete query retrieval is separate from clinical eligibility, study-family linkage and appraisal.

183 retrieved · 3 included · 0 excluded · 180 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

"Retatrutide"[Title/Abstract] OR "LY3437943"[Title/Abstract]

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T10:58:56.305398+00:00 · HTTP 200 · SHA-256 b01923361dd49ce1487a6d0389420eaa1d65a089aaa90f65be24b033eb7e0de2.

  • Open the source endpoint ↗

    Retrieved 2026-09-15T12:29:25.675375+00:00 · HTTP 200 · SHA-256 d8c7870bc5dde3348e023caea8033f67fe7dfdcca50ae7fc8658c4fe08d1b42b.

  • Open the source endpoint ↗

    Retrieved 2026-09-15T12:29:28.311164+00:00 · HTTP 200 · SHA-256 f24393a66f03f28c257bbc83f1c6f83ce7e11a93ca88aef5632b98c404c9021d.

  • Retrieved IDs completely represent this query response, not all relevant literature. Additional aliases, references and non-PubMed sources require separate searches.
  • Unscreened records may include animal or cell experiments, reviews, secondary analyses, mixtures, protocols and unrelated name matches.
  • Study-family mappings use available declared registry IDs; unresolved mappings do not create independent trial counts. Full-text, corrections and registry comparison remain separate work.
  • The selected newer trials are not a completed screen of this entire title/abstract search. Additional primary, secondary, safety and protocol reports remain to be appraised.

Showing 25 of 183 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. PubMed 42250575 — include: Selected primary trial report; the abstract and record metadata were read. Inclusion is not completed full-text appraisal. Study families: NCT06354660.
  2. PubMed 37385280 — include: Selected published human report; abstract reviewed. Full-text and study-family appraisal remain separate. Study families: NCT04867785.
    Bibliographic record recheck · 2026-09-15

    The selected PubMed XML payload matches the previous reviewed snapshot. This is a metadata recheck, not a new appraisal or a finding that no corrections exist. Open PubMed record ↗

    SHA-256 766a11f2d979da96a8a2b79353159b0e0472215d1e391b8f8f5d09a142c5fdcd.

  3. PubMed 37366315 — include: Selected published human report; abstract reviewed. Full-text and study-family appraisal remain separate. Study families: NCT04881760.
    Bibliographic record recheck · 2026-09-15

    The selected PubMed XML payload matches the previous reviewed snapshot. This is a metadata recheck, not a new appraisal or a finding that no corrections exist. Open PubMed record ↗

    SHA-256 167232d6f5d1818faabbc3d98c283b2ffad85563d5e10720f8e23347bba1ad1b.

  4. PubMed 42734711 — not screened: Name-query match awaiting clinical eligibility screening.
  5. PubMed 42722378 — not screened: Name-query match awaiting clinical eligibility screening.
  6. PubMed 42721492 — not screened: Name-query match awaiting clinical eligibility screening.
  7. PubMed 42690722 — not screened: Name-query match awaiting clinical eligibility screening.
  8. PubMed 42688617 — not screened: Name-query match awaiting clinical eligibility screening.
  9. PubMed 42683980 — not screened: Name-query match awaiting clinical eligibility screening.
  10. PubMed 42682157 — not screened: Name-query match awaiting clinical eligibility screening.
  11. PubMed 42673585 — not screened: Name-query match awaiting clinical eligibility screening.
  12. PubMed 42669023 — not screened: Name-query match awaiting clinical eligibility screening.
  13. PubMed 42649514 — not screened: Name-query match awaiting clinical eligibility screening.
  14. PubMed 42630988 — not screened: Name-query match awaiting clinical eligibility screening.
  15. PubMed 42624955 — not screened: Name-query match awaiting clinical eligibility screening.
  16. PubMed 42608321 — not screened: Name-query match awaiting clinical eligibility screening.
  17. PubMed 42603384 — not screened: Name-query match awaiting clinical eligibility screening.
  18. PubMed 42602523 — not screened: Name-query match awaiting clinical eligibility screening.
  19. PubMed 42590128 — not screened: Name-query match awaiting clinical eligibility screening.
  20. PubMed 42568490 — not screened: Name-query match awaiting clinical eligibility screening.
  21. PubMed 42567543 — not screened: Name-query match awaiting clinical eligibility screening.
  22. PubMed 42562129 — not screened: Name-query match awaiting clinical eligibility screening.
  23. PubMed 42559975 — not screened: Name-query match awaiting clinical eligibility screening.
  24. PubMed 42556625 — not screened: Name-query match awaiting clinical eligibility screening.
  25. PubMed 42536830 — not screened: Name-query match awaiting clinical eligibility screening.

FDA search

Active-ingredient name query in openFDA Drugs@FDA. Returned application identities include salt forms and combination products; exact indications, approval conditions, supplements and marketing status require document-level review.

0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

products.active_ingredients.name:"RETATRUTIDE"

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T11:10:25.734629+00:00 · HTTP 404 · SHA-256 57b1e7534d003e4246182162fd2469cdf038de39405056f44fc006715e5496da.

  • Zero results describe this query response only, not absence of FDA approval or worldwide nonapproval.
  • This endpoint does not inventory every label, advisory proceeding, safety communication or regulatory document. Application inclusion does not establish current marketing or approval of every use.

Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

    EMA search

    Local matching in the pinned EMA medicines feed; document matches also use identified EMA product numbers. This is not every national European record.

    0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

    Search terms, record decisions and remaining work

    Case-insensitive word-boundary identity terms: ["Retatrutide", "LY3437943"]

    Source retrievals and payload pins
    • Open the source endpoint ↗

      Retrieved 2026-09-15T08:34:22.905972+00:00 · HTTP 200 · SHA-256 a947c2b8a56ac2b92ec96156843f262f5e516f83b375d6791d67a8f6dc695729.

    • Document appraisal and national European sources remain open.
    • Zero matches apply only to these feed fields and terms; orphan designation is not approval.

    Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

      EMA search

      Local matching in the pinned EMA documents feed; document matches also use identified EMA product numbers. This is not every national European record.

      1 retrieved · 0 included · 0 excluded · 1 awaiting a decision · 0 full-text appraisals

      Search terms, record decisions and remaining work

      Case-insensitive word-boundary identity terms: ["Retatrutide", "LY3437943"]

      Source retrievals and payload pins
      • Open the source endpoint ↗

        Retrieved 2026-09-15T08:34:29.167460+00:00 · HTTP 200 · SHA-256 c0c68d7d77783e0355cbc75bdd04772e9acc163236fc68abcd794477c4c3d439.

      • Document appraisal and national European sources remain open.
      • Zero matches apply only to these feed fields and terms; orphan designation is not approval.

      Showing 1 of 1 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

      1. EMA 70585 — not screened: Title-name match awaiting identity and document review. P/0336/2024 : EMA decision of 13 September 2024 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for retatrutide (EMEA-003258-PIP02-23)

      EMA search

      Local matching in the pinned EMA orphans feed; document matches also use identified EMA product numbers. This is not every national European record.

      0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

      Search terms, record decisions and remaining work

      Case-insensitive word-boundary identity terms: ["Retatrutide", "LY3437943"]

      Source retrievals and payload pins
      • Open the source endpoint ↗

        Retrieved 2026-09-15T08:34:31.262344+00:00 · HTTP 200 · SHA-256 7448bf4e77e3345b3f3fbb7062c335d2302d8ea458a246bbe8256ce48aad2806.

      • Document appraisal and national European sources remain open.
      • Zero matches apply only to these feed fields and terms; orphan designation is not approval.

      Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

        ClinicalTrials.gov search

        ClinicalTrials.gov name/alias discovery, including cited product names. Matches may concern combinations, background references or different formulations; identity and outcomes need screening.

        35 retrieved · 0 included · 0 excluded · 35 awaiting a decision · 0 full-text appraisals

        Search terms, record decisions and remaining work

        "Retatrutide" OR "LY3437943"

        Source retrievals and payload pins
        • Open the source endpoint ↗

          Retrieved 2026-09-15T11:26:50.840613+00:00 · HTTP 200 · SHA-256 3fc6de651362de593977ef6c2cad4f08b63878a90fdca2b11953f6f4e44527f6.

        • Registration is not evidence that a study succeeded, that results were published, or that a use is approved.
        • Other registries, unregistered studies and additional aliases remain outside this query.

        Showing 25 of 35 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

        1. ClinicalTrials.gov NCT04881760 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        2. ClinicalTrials.gov NCT06354660 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        3. ClinicalTrials.gov NCT05916560 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        4. ClinicalTrials.gov NCT06297603 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        5. ClinicalTrials.gov NCT05931367 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        6. ClinicalTrials.gov NCT06260722 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        7. ClinicalTrials.gov NCT06383390 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        8. ClinicalTrials.gov NCT05548231 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        9. ClinicalTrials.gov NCT07165028 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        10. ClinicalTrials.gov NCT06313528 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        11. ClinicalTrials.gov NCT06039826 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        12. ClinicalTrials.gov NCT05882045 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        13. ClinicalTrials.gov NCT04143802 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        14. ClinicalTrials.gov NCT06003465 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        15. ClinicalTrials.gov NCT04823208 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        16. ClinicalTrials.gov NCT05959096 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        17. ClinicalTrials.gov NCT06859268 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        18. ClinicalTrials.gov NCT05929066 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        19. ClinicalTrials.gov NCT05929079 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        20. ClinicalTrials.gov NCT07226947 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        21. ClinicalTrials.gov NCT06808802 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        22. ClinicalTrials.gov NCT07035093 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        23. ClinicalTrials.gov NCT05445232 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        24. ClinicalTrials.gov NCT03841630 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        25. ClinicalTrials.gov NCT06982859 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
        Explore status sources, recent additions, and coverage gaps

        Living status brief

        What is the current status of Retatrutide?

        In clinical trials; not FDA-approved. Published randomized trials, including a Phase 3 diabetes trial, report weight and blood-sugar changes over up to 48 weeks. FDA states that retatrutide has not been found safe and effective for any condition and has warned companies marketing it to consumers.↗↗↗↗↗

        The cited status sources were checked through July 22, 2026. This answer changes only through the profile’s visible version and correction history.

        Evidence present

        What records are connected here?

        Evidence lanes
        3
        Source years
        3
        Drugs@FDA applications
        0

        These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

        Latest source-dated record

        What changed most recently at a cited source?

        Clinical trials · source date November 13, 2026

        ClinicalTrials.gov record NCT06297603↗Added to PeptideScanner November 14, 2026

        Coverage gaps

        What remains unknown or unsupported?

        PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

        PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

        Explore the Evidence Map and record counts

        Evidence Map v1

        What kinds of records connect to Retatrutide?

        Compare collection coverage →

        This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

        27Selected dated records
        31Connected citations
        3Populated source years2024–2026
        3/4Record lanes present

        Registered human studies

        Trial composition

        8 of 9 selected trial records include at least one phase value; 8 of 9 include a status value in the retained structured contract.

        43 public history versions connect to 2 of these trial records across 4 submitted years. Open the record-history collection →

        PhasesPhase 3 7Phase 2 1
        Status at observationActive, not recruiting 4Completed 4

        A phase value is unavailable here for 1 selected record; this is not counted as “no phase.”

        A status value is unavailable here for 1 selected record; this is not counted as a trial status.

        PubMed bibliography

        Publication composition

        7 of 17 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

        Publication typesLetter 4Comment 3Journal Article 3

        Bibliography fields unavailable here for 10 selected records; the records remain visible as metadata observations.

        Regulatory and publication surfaces

        What is structurally connected?

        Drugs@FDA applications
        0
        FDA Federal Register documents
        0
        DailyMed SPL versions
        0
        Canonical profile
        Published
        Profile structured data
        Published
        Linked dated records
        27

        Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

        Profile publication history and record counts
        Source records by collection · 27 dated records

        Research hub

        Explore the Retatrutide evidence record

        Open all 27 records →
        27Dated records
        3Evidence types
        27Cited public sources
        3Source years

        Change ledger

        Recently changed for Retatrutide

        Open all 29 events →

        PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

        Profile status changed

        Retatrutide profile

        We added a plain-language reader guide with cited answers, published trial results from our human evidence review, current ClinicalTrials.gov records, and FDA’s current page on unapproved GLP-1 drugs (content current as of October 1, 2026), which states that retatrutide cannot be used in compounding.

        PeptideScanner change date
        November 14, 2026
        Evidence lane
        Profile
        Record added

        ClinicalTrials.gov record NCT05936151

        PeptideScanner retained ClinicalTrials.gov record NCT05936151 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was retatrutide.

        PeptideScanner change date
        November 14, 2026
        Cited source date
        November 9, 2026
        Evidence lane
        Clinical trials
        Record added

        ClinicalTrials.gov record NCT06297603

        PeptideScanner retained ClinicalTrials.gov record NCT06297603 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was retatrutide.

        PeptideScanner change date
        November 14, 2026
        Cited source date
        November 13, 2026
        Evidence lane
        Clinical trials

        Official-source collections

        Source records for Retatrutide

        Open the full research atlas →
        ClinicalTrials.gov8

        43 public history versions across these dated registry records; status labels apply only to each cited observation.

        1. NCT06297603Registry update November 13, 2026 · current at observation
        2. NCT07232719Registry update November 10, 2026 · current at observation
        3. NCT05936151Registry update November 9, 2026 · completed at observation
        Explore all selected trial records →Explore all public record history →

        Evidence types

        Coverage by source year

        Selected records span July 20, 2024 to November 13, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

        Continue exploring

        Profiles with overlapping source-year coverage

        Open the research atlas →

        These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

        Organizations and trial records named in cited sources

        Organizations named in cited records

        • Eli Lilly and Company1
        • U.S. Food and Drug Administration2

        Trial records

        Dated updates connected to this profile · 27

        Updates connected to this profile

        Open the full cross-source timeline →
        1. Clinical trials

          ClinicalTrials.gov record NCT06297603↗

          PeptideScanner retained ClinicalTrials.gov record NCT06297603 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was retatrutide.↗

        2. Clinical trials

          ClinicalTrials.gov record NCT07232719↗

          PeptideScanner retained ClinicalTrials.gov record NCT07232719 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was retatrutide.↗

        3. Clinical trials

          ClinicalTrials.gov record NCT05936151↗

          PeptideScanner retained ClinicalTrials.gov record NCT05936151 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was retatrutide.↗

        4. Literature metadata

          Unapproved GLP-1 Drugs Retatrutide and Zenagamtide Sold Online Are No Bargain.↗

          PubMed lists PMID 42853576 in JAMA as Journal Article, with publication-date metadata of 2026-11-03 (day precision). PeptideScanner associated the retained record with the identity slug retatrutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

        5. Literature metadata

          Retatrutide in adults with obesity and type 2 diabetes: what have we learned from TRIUMPH-2?↗

          PubMed lists PMID 42849462 in Lancet (London, England) as Journal Article, with publication-date metadata of 2026-10-10 (day precision). PeptideScanner associated the retained record with the identity slug retatrutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

        6. Clinical trials

          ClinicalTrials.gov record NCT07035093↗

          PeptideScanner retained ClinicalTrials.gov record NCT07035093 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-25, and PeptideScanner's reviewed identity mapping was retatrutide.↗

        7. Clinical trials

          ClinicalTrials.gov record NCT06383390↗

          PeptideScanner retained ClinicalTrials.gov record NCT06383390 at 2026-09-09T19:17:17.103Z. Its registry update date was 2026-08-24, and PeptideScanner's reviewed identity mapping was retatrutide.↗

        8. Clinical trials

          ClinicalTrials.gov record NCT05929066↗

          PeptideScanner retained ClinicalTrials.gov record NCT05929066 at 2026-09-09T19:17:17.407Z. Its registry update date was 2026-08-21, and PeptideScanner's reviewed identity mapping was retatrutide.↗

        9. Literature metadata

          PubMed record PMID 42567543↗

          PeptideScanner retained PubMed bibliographic metadata for PMID 42567543 at 2026-08-10T10:49:13.603Z. PubMed recorded a metadata revision date of 2026-08-07 and an Entrez history date of 2026-08-07. PeptideScanner associated this retained record with the identity slug retatrutide. These dates describe PubMed metadata history, not the article's original publication date.↗

        10. Literature metadata

          PubMed record PMID 38323122↗

          PeptideScanner retained PubMed bibliographic metadata for PMID 38323122 at 2026-08-10T10:49:06.879Z. PubMed recorded a metadata revision date of 2026-07-31 and an Entrez history date of 2024-02-07. PeptideScanner associated this retained record with the identity slug retatrutide. These dates describe PubMed metadata history, not the article's original publication date.↗

        11. Clinical trials

          ClinicalTrials.gov record NCT05882045↗

          PeptideScanner retained ClinicalTrials.gov record NCT05882045 at 2026-08-10T18:10:03.944Z. Its registry update date was 2026-07-30, and PeptideScanner's reviewed identity mapping was retatrutide.↗

        12. Clinical trials

          ClinicalTrials.gov record NCT05929079↗

          PeptideScanner retained ClinicalTrials.gov record NCT05929079 at 2026-08-10T18:10:04.224Z. Its registry update date was 2026-07-30, and PeptideScanner's reviewed identity mapping was retatrutide.↗

        Citations

        Sources

        Coverage and sources →

        Numbered markers in the text point here. Each link opens the original public record.

        1. 1
          Retatrutide in Participants With Type 2 Diabetes and Renal Impairment · record history version 25 · last update posted 2026-07-20 ↗

          ClinicalTrials.gov · Official source · Source checked July 22, 2026

        2. 2
          FDA’s concerns with unapproved GLP-1 drugs used for weight loss · content current as of October 1, 2026 ↗

          U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

        3. 3
          Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial (2023) · PMID 37366315 ↗

          The New England Journal of Medicine · Official source · Source checked November 14, 2026

        4. 4
          Retatrutide for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA (2023) · PMID 37385280 ↗

          The Lancet · Official source · Source checked November 14, 2026

        5. 5
          Efficacy and safety of retatrutide in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial (2026) · PMID 42250575 ↗

          The Lancet · Official source · Source checked November 14, 2026

        6. 6
          ClinicalTrials.gov record NCT05882045 · retained source version 2026-07-30:d21e38ddcccc7ab66ec1bddaa910bf3c7a7a3149a43f4ac27918a9e80f8452da ↗

          ClinicalTrials.gov · Official source · Source checked August 14, 2026

        7. 7
          ClinicalTrials.gov record NCT05929079 · retained source version 2026-07-30:d0cad2c0ebfa7ce1f2af088a52c397680123509e21999e7837a0b2b517e9ef04 ↗

          ClinicalTrials.gov · Official source · Source checked August 14, 2026

        8. 8
          ClinicalTrials.gov record NCT05929066 · retained source version 2026-08-21:fa2b7b67fa10d746247b3082eeaba2f5a16212dc2a870697f3b8369f43983d27 ↗

          ClinicalTrials.gov · Official source · Source checked September 9, 2026

        9. 9
          ClinicalTrials.gov record NCT06383390 · retained source version 2026-08-24:4bb37a90f79acd41fc8e0a5c8b4745c3c9610a0993eab8f502e836929a21c5ff ↗

          ClinicalTrials.gov · Official source · Source checked September 9, 2026

        10. 10
          ClinicalTrials.gov record NCT06297603 · retained source version 2026-11-13:c86dcf0120caf546c9c9fa9df1808025579fcf0e33236ed212dc3df861690ab7 ↗

          ClinicalTrials.gov · Official source · Source checked November 14, 2026